Lennox-Gastaut Syndrome clinical trials at UCSF
2 in progress, 1 open to eligible people
Lennox-Gastaut syndrome is a severe epilepsy with mixed seizures. UCSF is conducting research to see if soticlestat, when added to usual treatments, helps control seizures better. The study involves participants of various ages to understand its effectiveness broadly.
Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
open to eligible people ages 2-56
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of seizures in children and adults with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS). Participants will receive their standard anti-seizure therapy, plus tablets of soticlestat. There will be scheduled visits and follow-up phone calls throughout the study.
San Francisco, California and other locations
RNS System LGS Feasibility Study
Sorry, in progress, not accepting new patients
To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or older with Lennox Gastaut Syndrome (LGS) who are refractory to antiseizure medications. The intent is to determine the feasibility and the optimal design of a subsequent pivotal study in order to expand the indication for use for the RNS System as a treatment for patients with medically intractable LGS.
San Francisco, California and other locations
Our lead scientists for Lennox-Gastaut Syndrome research studies include Joseph Sullivan.